Connect with us

Marknadsnyheter

Fortum Värme offentliggör återköpserbjudande och en eventuell nyemission

Published

on

to, nov 09, 2017 10:00 CET

NOT FOR DISTRIBUTION IN OR INTO OR TO ANY PERSON LOCATED OR RESIDENT IN THE UNITED STATES, ITS TERRITORIES AND POSSESSIONS (INCLUDING PUERTO RICO, THE U.S. VIRGIN ISLANDS, GUAM, AMERICAN SAMOA, WAKE ISLAND AND THE NORTHERN MARIANA ISLANDS, ANY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA) OR TO ANY U.S. PERSON (AS DEFINED IN REGULATION S OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED) (THE ”SECURITIES ACT”) OR IN ANY JURISDICTION WHERE IT IS UNLAWFUL TO RELEASE, PUBLISH OR DISTRIBUTE THIS DOCUMENT. THE DISTRIBUTION OF THIS DOCUMENT IN CERTAIN JURISDICTIONS (IN PARTICULAR, THE UNITED STATES, THE UNITED KINGDOM, FRANCE, BELGIUM AND ITALY) MAY BE RESTRICTED BY LAW.

** Fortum Värme announces a tender offer and a potential new issue **

AB Fortum Värme Holding samägt med Stockholm stad (publ) (the “
Issuer
” and “
Fortum Värme
”) has mandated Danske Bank A/S (“
Danske Bank
”),  Nordea Bank AB (publ) (“
Nordea
”) and Skandinaviska Enskilda Banken AB (publ) (“
SEB
”)(the “
Joint Bookrunners
” and/or “
Dealer Managers
”) to arrange investor meetings starting on 15 November 2017. The Issuer will thereafter issue a SEK denominated senior unsecured capital markets transaction, subject to market conditions.

Furthermore, the Issuer today announces its invitations to the holders of its outstanding SEK 1,000,000,000 FRN notes due 17 September 2018 (ISIN: SE0007525944) (the “
Notes
”) to tender their Notes for cash (the “
Tender Offer
”) subject to the satisfaction of the New Financing Conditions (see below) being met.

The Tender Offer is made on the terms and subject to the conditions set out below.

Purchase price

Subject to the applicable minimum denomination in respect of the Notes, the Issuer offers to purchase the Notes as follows: the purchase price payable per Note having a nominal amount of SEK 1,000,000 will be 100.458 per cent (the “
Purchase Price
”).

The Issuer will also pay an amount equal to any accrued and unpaid interest on the relevant Notes from, but excluding, the interest payment date for the Notes immediately preceding the settlement date for the purchase of the Notes (the “
Settlement Date
”) up to, and including, the Settlement Date (“
Accrued Interest
”).

New Financing Conditions

Today the Issuer also announces its intention to issue new SEK denominated notes with an expected long 7 year maturity of (the “
New Notes
”) in the near future. 

The Issuer’s acceptance of Notes validly tendered for purchase pursuant to the Tender Offer is conditional upon, in the absolute and sole discretion and determination of the Issuer, (i) the terms and conditions of the New Notes are satisfactory to the Issuer, including, but not limited to, as to the price of the New Notes, (ii) the successful completion (including the receipt of funds by or on behalf of the Issuer) of the issuance of New Notes, which will enable the Issuer to finance, in whole or in part, the Purchase Price and Accrued Interest of the total amount of Notes validly tendered and accepted for purchase pursuant to the Tender Offer (together “
New Financing Conditions
”).

Registered holders of the Notes and beneficial owners who hold their Notes via nominees or custodians (“
Noteholders
”) can only participate in the Tender Offer by submitting a valid tender instruction (“
Tender Instruction
”) as further specified below under “Participation”. The Issuer’s acceptance of Notes validly tendered in accordance with the terms and conditions of the Tender Offer will be irrevocable, but in any case subject to the Transaction Cap described below and the satisfaction of the New Financing Conditions.

Transaction Cap

The tendered amount of Notes accepted by the Issuer will be capped at the total nominal amount of the issue of the New Notes (the “
Transaction Cap
”). If the Issuer decides to accept for purchase valid Tender Instructions made pursuant to the Tender Offer and the aggregate nominal amount of Notes validly tendered pursuant to the Tender Offer is greater than the nominal amount of the New Notes, the Issuer may accept such Notes for purchase on a pro rata basis (see below for further details), subject to the minimum denomination of SEK 1,000,000.

In the event of any scaling in the acceptance of Notes to be purchased, the Issuer will (i) firstly accept in full Tender Instructions from investors who subscribe for New Notes, (ii) secondly accept either all or none of the Tender Instructions of Notes with a total nominal amount of SEK 1,000,000 and (iii) thirdly accept all other Tender Instructions of Notes with a total nominal size above SEK 1,000,000 on a pro rata basis. The acceptance of Tender Instructions of Notes will be rounded to a multiple of SEK 1,000,000 and any scaling made by the Issuer is binding on all Noteholders who validly tendered their Notes.

Purpose of the Tender Offer

The Tender Offer is being made as part of the Issuer’s commitment to exercise active management of its liabilities. The purpose of the Tender Offer is to pro-actively manage the Issuer’s upcoming debt redemptions, to extend its debt maturity profile and to allow current holders to roll their current position into the New Notes.

Priority in New Notes

Noteholders who submit a valid Tender Instruction will be eligible to receive a priority in the allocation of New Notes. Such priority in allocation will match in size the nominal volume submitted and accepted for tender, subject to eligibility with the minimum denomination requirements of the New Notes.

Restrictions
 

This announcement does not constitute a sale of New Notes. The New Notes are not being, and will not be, offered or sold in the United States. Nothing in this announcement constitutes an offer to sell or the solicitation of an offer to buy the New Notes in the United States or any other jurisdiction. Securities may not be offered, sold or delivered in the United States absent registration under, or an exemption from the registration requirements of, the Securities Act. The New Notes have not been, and will not be, registered under the Securities Act or the securities laws of any state or other jurisdiction of the United States and may not be offered, sold or delivered, directly or indirectly, within the United States or to, or for the account or benefit of, U.S. persons (as defined in Regulation S under the Securities Act).

Investors who wish to buy New Notes should contact their sales contact at one of the Joint Bookrunners to obtain all relevant documentation.

Deadline

The Tender Offer expires at 12:00 CET on 16 November 2017, unless extended, re-opened, withdrawn or terminated at the sole discretion of the Issuer. The Issuer will announce the results and whether any Notes will be accepted under the Tender Offer as soon as reasonably practicable after the pricing of the New Notes. Settlement of the Tender Offer is expected to occur at or around 24 November 2017. Settlement of the transactions pursuant to the Tender Offer will occur as a secondary trade via one of the Dealer Managers.

Subject to applicable law, the Issuer may, in its sole and absolute discretion, extend, re-open, amend or waive any condition of or terminate the Tender Offer at any time. Noteholders are advised to read carefully this announcement for the details of and information on the procedures for participating in the Tender Offer.

Noteholders will not receive any further documents regarding the Tender Offer and should instead contact one of the Dealer Managers on the details below.

Participation

Only Noteholders who are eligible counterparts to minimum one of the Dealer Managers may participate in this Tender Offer and Noteholders must contact one of the Dealer Managers to receive an application form that includes the details of how to participate in the Tender Offer. Tender Instructions given via the application form are irrevocable by the Noteholders, except for in the limited circumstances described in the application form. 

Noteholders should consult their own tax, accounting, financial and legal advisers regarding the suitability to themselves of the tax or accounting consequences of participating in the Tender Offer.

To obtain an application form and participate in the Tender Offer please contact one of the Dealer Managers at the details below:

CONTACT INFORMATION

Joint Bookrunners and Dealer Managers

Skandinaviska Enskilda Banken AB
(publ)
 

Email: liabilitymanagement@seb.se 

AB Fortum Värme Holding samägt med Stockholm stad (publ)

Heiko Bechtel

Head of Treasury

Heiko.bechtel@fortum.com       

This is information that AB Fortum Värme Holding samägt med Stockholms stad (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person Heiko Bechtel, Head of Treasury at 10:00 CET on 9 November 2017.

DISCLAIMER
 

This announcement contains important information which should be read carefully before any decision is made with respect to the Tender Offer. If any holder is in any doubt as to the action it should take or is unsure of the impact of the Tender Offer, it is recommended to seek its own financial and legal advice, including as to any tax consequences, from its stockbroker, bank manager, solicitor, accountant or other independent financial or legal adviser. Any holder whose Notes are held on its behalf by a broker, dealer, bank, custodian, trust company or other nominee or intermediary must contact such entity if it wishes to tender such Notes pursuant to the Tender Offer.

Neither the Issuer nor the Dealer Managers

nor their respective directors, employees or affiliates makes any recommendation as to whether holders of Notes should tender Notes for purchase pursuant to the Tender Offer. 

Offer and Distribution Restrictions

This announcement does not constitute an invitation to participate in the Tender Offer in any jurisdiction in which, or to any person to or from whom, it is unlawful to make such invitation or for there to be such participation under applicable securities laws. The distribution of this announcement in certain jurisdictions may be restricted by law. Persons into whose possession this announcement comes are required by each of the Issuer and the Dealer Managers to inform themselves about and to observe any such restrictions.

United States

The Tender Offer is not being made and will not be made, directly or indirectly, in or into, or by use of the mails of, or by any means or instrumentality of interstate or foreign commerce of, or of any facilities of a national securities exchange of, the United States or to any U.S. Person (as defined in Regulation S of the United States Securities Act of 1933, as amended (each a ”
U.S. Person
”)). This includes, but is not limited to, facsimile transmission, electronic mail, telex, telephone, the internet and other forms of electronic communication. Accordingly, copies of this announcement and any other documents or materials relating to the Tender Offer are not being, and must not be, directly or indirectly, mailed or otherwise transmitted, distributed or forwarded (including, without limitation, by custodians, nominees or trustees) in or into the United States or to a U.S. Person and the Notes cannot be tendered in the Tender Offer by any such use, means, instrumentality or facility or from or within or by persons located or resident in the United States or by any U.S. Person. Any purported tender of Notes in the Tender Offer resulting directly or indirectly from a violation of these restrictions will be invalid and any purported tender of Notes made by a person located in the United States, a U.S. Person, by any person acting for the account or benefit of a U.S. Person, or by any agent, fiduciary or other intermediary acting on a non-discretionary basis for a principal giving instructions from within the United States will be invalid and will not be accepted.

Each holder of Notes participating in the Offer will represent that it is not a U.S. Person, it is not located in the United States and is not participating in the Tender Offer from the United States, or it is acting on a nondiscretionary basis for a principal located outside the United States that is not giving an order to participate in the Tender Offer from the United States and who is not a U.S. Person. For the purposes of this and the above paragraph, ”
United States”
means the United States of America, its territories and possessions (including Puerto Rico, the U.S. Virgin Islands, Guam, American Samoa, Wake Island and the Northern Mariana Islands), any state of the United States of America and the District of Columbia.

United Kingdom

The communication of this announcement and any other documents or materials relating to the Tender Offer is not being made, and such documents and/or materials have not been approved, by an authorised person for the purposes of section 21 of the Financial Services and Markets Act 2000, as amended. Accordingly, such documents and/or materials are not being distributed to, and must not be passed on to, the general public in the United Kingdom. The communication of such documents and/or materials as a financial promotion is only being made to those persons in the United Kingdom falling within the definition of investment professionals (as defined in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the ”
Financial Promotion Order
”)) or any other persons to whom it may otherwise lawfully be made under the Financial Promotion Order.

General

Neither this announcement nor the electronic transmission thereof constitutes an offer to buy or the solicitation of an offer to sell Notes (and tenders of Notes for purchase pursuant to the Tender Offer will not be accepted from holders) in any circumstances in which such offer or solicitation is unlawful. In those jurisdictions where the securities, blue sky or other laws require the Tender Offer to be made by a licensed broker or dealer and the Dealers Managers or any of their affiliates are such a licensed broker or dealer in any such jurisdiction, the Tender Offer shall be deemed to be made by such affiliate, as the case may be, in such jurisdiction.

Each holder participating in the Tender Offer will be deemed to give certain other representations in respect of the other jurisdictions referred to above and generally as set out in the application form for participating in the Tender Offer available from the Dealer Managers 

Any tender of Notes for purchase pursuant to the tender Offer from a holder that is unable to make these representations will not be accepted.

The Issuer reserves the right, in its sole and absolute discretion, to investigate, in relation to any tender of Notes for purchase pursuant to the Tender Offer, whether any such representation given by a holder is correct and, if such investigation is undertaken and as a result the Issuer determines (for any reason) that such representation is not correct, such tender or submission may be rejected. 

Fortum Värme skapar energin i framtidens städer

Fortum Värme skapar ett behagligt inomhusklimat till boende och verksamma i Stor-Stockholm. Det lokala energibolaget producerar resurseffektiv fjärrvärme, fjärrkyla och el och ägs till lika delar av Fortum och Stockholms stad. Tillsammans med kunder och stockholmare har Fortum Värme bidragit till att Stockholm räknas som en av världens mest hållbara huvudstäder.

Taggar:

Continue Reading

Marknadsnyheter

Slottsviken publicerar årsredovisning

Published

on

By

Styrelsen får härmed avge årsredovisning avseende räkenskapsåret 2023

Årsredovisningen finns tillgänglig på Bolagets webbplats www.slottsviken.se

För mer information kontakta:

Jakob Österberg, VD

Slottsviken Fastighetsaktiebolag (publ)

Telefon 018-19 49 50

E-post jakob.osterberg@slottsviken.se

 
Om Slottsviken Fastighetsaktiebolag:

Slottsviken är ett fastighetsbolag som förvärvar, förvaltar och utvecklar attraktiva fastigheter i stadsnära områden. Bolaget grundades 1983 och har sitt huvudkontor i Göteborg. Slottsviken är noterat på Spotlight Stock Market sedan 1997 och handlas via banker och fondkommissionärer.

Continue Reading

Marknadsnyheter

RaySearch och C-RAD tecknar samarbetsavtal

Published

on

By

RaySearch Laboratories AB (pub) och C-RAD AB är glada att kunna tillkännage ett samarbetsavtal som syftar till att gemensamt utveckla innovativa lösningar och produkter för att förbättra kvaliteten på strålbehandling.

Fokus för samarbetet är att undersöka hur C-RAD:s ytskanningsteknologi kan utnyttjas vid dosplanering i RaySearchs dosplaneringssystem RayStation. Idag används ytorna från Catalyst+, C-RAD:s system för ytguidad strålbehandling, under bildtagning och behandling. Genom att göra Catalysts+ ytor tillgängliga i RayStation®* skapas många användningsmöjligheter. En sådan är att expandera en CBCT-bild, som har ett begränsat avbildningsområde, genom att använda information från ytskanningen. Detta kommer att leda till ett mer komplett återskapande av patientens anatomi, vilket i sin tur resulterar i ett mer tillförlitligt underlag för kliniska beslut. Som ett första resultat av samarbetet kommer ovan beskrivna tillämpning att demonstreras under den pågående mässan ESTRO. Därefter kommer andra användningsområden av företagens respektive produkter att utforskas.

Cecilia de Leeuw, vd och koncernchef, C-RAD: “Vi är mycket glada över samarbetet med RaySearch, genom vilket vi ska förbättra och hitta nya innovativa lösningar i vår gemensamma kamp mot cancer.”

Johan Löf, grundare och vd, RaySearch: “Jag ser fram emot att samarbeta med C-RAD, vars kontor dessutom ligger nära oss i Sverige. Den ytterligare information om patientens anatomi som tillhandahålls genom ytskanning via Catalyst+ har potential att avsevärt förbättra olika steg i dosplaneringsprocessen för strålbehandling i RayStation.”

För mer information vänligen kontakta: 
Johan Löf, grundare och vd, RaySearch Laboratories AB (publ) 
Tel: +46 (0) 8 510 530 00 
johan.lof@raysearchlabs.com  

Om C-RAD 
C-RAD utvecklar ytskanningsteknologi för strålterapi för att möjliggöra en mycket exakt dosavgivning till tumören och samtidigt skydda frisk vävnad från oönskad exponering. Med hjälp av höghastighets 3D-kameror i kombination med förstärkt verklighet stöder C-RAD den initiala patientpositioneringen och övervakar patientens rörelser under behandlingen för att säkerställa hög tillförlitlighet, ett effektivt arbetsflöde och ökad noggrannhet. C-RAD övervakar patientens rörelse utan att använda markörer eller ytterligare dos för att ge den högsta nivån av patientsäkerhet och komfort.
 C-RAD AB är noterat på Nasdaq Stockholm. Mer information finns på c-rad.com.

Om RaySearch 
RaySearch Laboratories AB (publ) är ett medicintekniskt företag som utvecklar innovativa mjukvarulösningar för att förbättra cancervården. RaySearch marknadsför RayStation®* dosplaneringssystem (TPS) och onkologiinformations-systemet (OIS) RayCare®*. De senaste tilläggen i RaySearchs produktlinje är RayIntelligence® och RayCommand®*. RayIntelligence är ett molnbaserat analyssystem för onkologi (OAS) som cancerkliniker kan använda för att samla in, strukturera och analysera data. Behandlingsstyrsystemet (TCS) RayCommand är utformat som en länk mellan behandlingsmaskinen och systemen för dosplanering och onkologiinformation. 

Programvara från RaySearch har sålts till drygt 1 000 kliniker i 43 länder. Företaget grundades år 2000 som en avknoppning från Karolinska Institutet i Stockholm och aktien är noterad på Nasdaq Stockholm sedan 2003. Mer information finns på raysearchlabs.com. 
 
Om RayStation 
RayStation®* är ett flexibelt, innovativt dosplaneringssystem som används av många ledande cancercenter världen över. Det kombinerar unika funktioner för adaptiv terapi, flermålsoptimering och marknadsledande algoritmer för optimering av behandlingsplaner för HDR-brachyterapi och extern strålbehandling med fotoner, elektroner och protoner samt heliumjoner och koljoner. RayStation har stöd för ett stort antal behandlingsmaskiner. Det möjliggör att all behandlingsplanering kan göras i ett och samma system och att befintlig utrustning kan utnyttjas maximalt. RayStation kan integreras fullständigt med RayCare®*. Genom att harmonisera behandlingsplaneringen skapas bättre vård för cancerpatienter över hela världen. 

* Regulatoriskt godkännande krävs på vissa marknader.  

Taggar:

Continue Reading

Marknadsnyheter

Styrelsen i S2Medical AB (publ) har beslutat att bolagets årsredovisning även ska utgöra en kontrollbalansräkning, vilket till följd senarelägger bolagets årsredovisning

Published

on

By

Styrelsen i S2Medical AB (publ) (”S2Medical” eller ”Bolaget”) har i enlighet med aktiebolagslagen (25 kap 13 §), upprättat en kontrollbalansräkning (”KBR”) genom att besluta att balansräkningen i bolagets årsredovisning även skall utgöra en KBR. I syfte att ge Bolagets revisor tillräcklig frist för att möjliggöra denna process har styrelsen valt att senarelägga publiceringen av Bolagets årsredovisning med 6 dagar till den 9 maj 2024.

Beslutet att upprätta KBR grundar sig i att Bolagets egna kapital för närvarande är lägre än hälften av det registrerade aktiekapitalet. Styrelsen ser det inte som sannolikt att denna brist kommer att elimineras enbart genom regleringen av bolagets tillgångar och skulder i samband med genomförandet av den godkända rekonstruktionsplanen. Då både KBR och det positiva utfallet av företagsrekonstruktionen visar på livskraft anser styrelsen att en minskning av Bolagets registrerade aktiekapital är en tillräcklig åtgärd för att helt eliminera kapitalbristen. Styrelsen avser därför att föreslå en minskning av Bolagets registrerade aktiekapital. Förslaget kommer att inkluderas i kallelsen till Bolagets kommande årsstämma för beslut.

Vi ser positivt på framtiden och jag uppfattar detta som en nödvändig administrativ åtgärd för att justera ett oproportionerligt stort aktiekapital på över 16 miljoner SEK.” Säger Bolagets CEO, Petter Sivlér

Denna information är sådan som S2Medical AB är skyldigt att offentliggöra enligt EU:s marknadsmissbruksförordning (EU nr 596/2014). Informationen lämnades, genom angiven kontaktpersons försorg, för offentliggörande 2024-05-03 20:38 CET.

Kontaktuppgifter
Petter Sivlér – CEO, S2Medical AB (publ)
Telefon: +46 (0)8-70 000 50
E-post: petter.sivler@s2m.se

Certified Adviser
Vator Securities AB
Telefon +46 (0)8-580 065 99
Hemsida: www.vatorsec.se 
Epost: ca@vatorsec.se

Om S2Medical 
S2Medical AB (publ) är ett medicintekniskt bolag som utvecklar och säljer innovativa sårläkningsprodukter för hela sårläkningsprocessen med fokus på brännskador och kroniska sår. Bolaget har utvecklat eiratex®, ett nytt cellulosabaserat material för läkning av svåra brännskador och kroniska sår. Materialet läker sår effektivt och därmed minskar både lidande för patienter samt kostnader för hälso- och sjukvården. 

Aktiens kortnamn: S2M

Aktiens ISIN-kod: SE0011725084

Continue Reading

Trending

Copyright © 2017 Zox News Theme. Theme by MVP Themes, powered by WordPress.